Point72 Asset Management’s Tango Therapeutics TNGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-298,339
Closed -$9.33M – 4556
2026
Q2
$9.33M Sell
298,339
-235,598
-44% -$5.82M 0.01% 1332
2026
Q1
$11.2M Sell
533,937
-1,440,098
-73% -$20M 0.01% 1165
2025
Q4
$17.5M Sell
1,974,035
-945,415
-32% -$8.15M 0.02% 987
2025
Q3
$24.5M Buy
+2,919,450
New +$19.8M 0.04% 489
2024
Q3
– Sell
-447,107
Closed -$3.84M – 2350
2024
Q2
$3.84M Buy
+447,107
New +$3.45M 0.01% 922
2023
Q2
– Sell
-7,346
Closed -$29K – 2782
2023
Q1
$29K Buy
+7,346
New +$42.6K ﹤0.01% 1907

Other funds holding TNGX

Point72 Asset Management's TNGX Position: Q3 2026 in Review

Point72 Asset Management sold out of Tango Therapeutics (TNGX) in Q3 2026, closing a stake of 298,339 shares — an estimated $9.33M sold.

Point72 Asset Management first reported a position in TNGX in Q1 2023 and held it in 6 quarters. The position peaked at $24.5M in Q3 2025. 255 funds tracked by Wall St. Rank hold TNGX as of Q3 2026.

  • Point72 Asset Management reported no remaining Tango Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Point72 Asset Management sold 298,339 Tango Therapeutics shares in Q3 2026, an estimated $9.33M.
  • Point72 Asset Management first reported a position in Tango Therapeutics in Q1 2023 and held it in 6 quarters.
  • Point72 Asset Management's Tango Therapeutics position peaked at $24.5M in Q3 2025.
  • 255 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.